Academic Journal
Chemistry considerations for the clinical translation of oncology PET radiopharmaceuticals
| العنوان: | Chemistry considerations for the clinical translation of oncology PET radiopharmaceuticals |
|---|---|
| المؤلفون: | Allott, L, Aboagye, EO |
| المساهمون: | Imperial College Healthcare NHS Trust- BRC Funding, Medical Research Council |
| المصدر: | 2259 ; 2245 |
| بيانات النشر: | American Chemical Society |
| سنة النشر: | 2020 |
| المجموعة: | Imperial College London: Spiral |
| مصطلحات موضوعية: | Science & Technology, Life Sciences & Biomedicine, Medicine, Research & Experimental, Pharmacology & Pharmacy, Research & Experimental Medicine, radiopharmaceuticals, clinical translation, positron emission tomography, radiochemistry, metabolism, POSITRON-EMISSION-TOMOGRAPHY, NUCLEOPHILIC AROMATIC-SUBSTITUTION, RADIATION-DOSIMETRY, PRECLINICAL EVALUATION, LATE-STAGE, SOMATOSTATIN RECEPTORS, F-18 RADIOCHEMISTRY, AFFIBODY MOLECULE, CANCER, BIODISTRIBUTION, 0303 Macromolecular and Materials Chemistry, 1115 Pharmacology and Pharmaceutical Sciences |
| الوصف: | Positron emission tomography (PET) has proven to be an invaluable tool in the staging and management of disease in oncology; however, [18F]fluorodeoxyglucose ([18F]FDG) remains the most widely used PET radiopharmaceutical despite the large financial investment in novel radiotracer development. We report our perspective and experience of translating radiopharmaceuticals into clinical studies, discussing the PET development pipeline from a chemistry perspective. We hope that, by identifying potential points of attrition along the pipeline and suggesting solutions to these problems, we may help others take their preclinical radiotracers into human studies. This review focuses primarily on the development of fluorine-18 radiopharmaceuticals, although the broader field of radiometal chemistry is considered where the translation journey is similar. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1543-8384 |
| Relation: | Molecular Pharmaceutics; http://hdl.handle.net/10044/1/81913; RDC04 |
| DOI: | 10.1021/acs.molpharmaceut.0c00328 |
| الاتاحة: | http://hdl.handle.net/10044/1/81913 https://doi.org/10.1021/acs.molpharmaceut.0c00328 |
| Rights: | © 2020 American Chemical Society. This document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.molpharmaceut.0c00328 |
| رقم الانضمام: | edsbas.1E9F31A6 |
| قاعدة البيانات: | BASE |
| تدمد: | 15438384 |
|---|---|
| DOI: | 10.1021/acs.molpharmaceut.0c00328 |